MRSN — Mersana Therapeutics Share News
0.000.00%
Last trade - 00:00- $145.16m
- $88.77m
- $40.50m
Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Mersana rises on FDA's 'fast track' tag for cancer drug, early-stage trial data
Mersana Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Mersana Therapeutics Provides Business Update And Announces Q3 2024 Financial Results
Brief: Mersana Therapeutics Q3 EPS USD -0.09
Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Mersana Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Mersana Therapeutics Q2 EPS USD -0.2
Mersana Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Mersana Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Mersana Therapeutics Q1 EPS USD -0.16
Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
U.S. RESEARCH ROUNDUP-Okta, Salesforce, Sarepta Therapeutics
Mersana Therapeutics Inc reports results for the quarter ended in December - Earnings Summary